Drug intelligence / Profile preview

MS011

Development stage: Preclinical
Lead developer: Medimscience
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MS011 is a preclinical monoclonal antibody developed by Medimscience (also known as Sisioai Biopharma) for the treatment of solid tumors. It specifically targets MT011, which is described as a proprietary macrophage-related protein. The therapeutic mechanism involves the modulation of macrophage activity within the tumor microenvironment, a strategy aimed at overcoming immune suppression and enhancing anti-tumor immune responses. As a targeted immunotherapy, MS011 is designed to inhibit tumor growth by interacting with this specific macrophage-associated biological pathway.

Targets

MAPT (Microtubule-associated protein tau)

Beyond the preview

Go deeper on MS011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MS011.

Explore the full profile